Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with survival rates rarely exceeding 10% at 5 years despite advances in surgery and systemic therapy. While tumour biology and stage are well-established prognostic factors, the role of tumour location—head versus body/tail—has remained controversial, with prior studies yielding inconsistent results.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with survival rates rarely exceeding 10% at 5 years despite advances in surgery and systemic therapy. While tumour biology and stage are well-established prognostic factors, the role of tumour location—head versus body/tail—has remained controversial, with prior studies yielding inconsistent results.
Problem Statement
Existing evidence on the prognostic impact of tumour location in PDAC is limited by heterogeneity in study design, small sample sizes, and inadequate adjustment for confounding variables. This uncertainty creates difficulty in clinical decision-making, particularly regarding surgical risk stratification, perioperative planning, and patient counselling.
Summary
This large multi-institutional TriNetX analysis provides robust evidence that tumor location significantly influences outcomes after resection. Tumors located in the pancreatic head are associated with higher perioperative mortality, increased risk of sepsis, and worse long-term survival compared to body/tail tumors. Even after propensity matching, head tumors demonstrated shorter median survival and higher overall mortality, confirming tumor location as an independent prognostic factor. These findings highlight the need for location-specific surgical strategies, risk assessment, and postoperative management to improve outcomes in PDAC.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.